KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 105 filers reported holding KEROS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,742,242 | -22.9% | 54,650 | -2.8% | 0.00% | – |
| Q2 2023 | $2,258,638 | -30.1% | 56,213 | -25.7% | 0.00% | – |
| Q1 2023 | $3,231,066 | +2.0% | 75,669 | +14.8% | 0.00% | – |
| Q4 2022 | $3,166,488 | +58.5% | 65,941 | +24.2% | 0.00% | – |
| Q3 2022 | $1,998,000 | +86.6% | 53,110 | +37.0% | 0.00% | – |
| Q2 2022 | $1,071,000 | -42.5% | 38,769 | +13.1% | 0.00% | – |
| Q1 2022 | $1,864,000 | +1.6% | 34,289 | +9.3% | 0.00% | – |
| Q4 2021 | $1,835,000 | +53.8% | 31,363 | +4.0% | 0.00% | – |
| Q3 2021 | $1,193,000 | +251.9% | 30,147 | +277.2% | 0.00% | – |
| Q2 2021 | $339,000 | -62.0% | 7,993 | -44.8% | 0.00% | – |
| Q1 2021 | $892,000 | +502.7% | 14,487 | +590.2% | 0.00% | – |
| Q4 2020 | $148,000 | +289.5% | 2,099 | +114.6% | 0.00% | – |
| Q3 2020 | $38,000 | -89.2% | 978 | -89.6% | 0.00% | – |
| Q2 2020 | $351,000 | – | 9,363 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 396,911 | $21,584,000 | 5.10% |
| Deep Track Capital, LP | 1,380,306 | $75,061,000 | 4.81% |
| Opaleye Management Inc. | 265,750 | $14,451,000 | 4.49% |
| Octagon Capital Advisors LP | 340,214 | $18,501,000 | 4.00% |
| First Light Asset Management, LLC | 658,145 | $35,790,000 | 3.16% |
| Altium Capital Management LP | 126,000 | $6,852,000 | 2.29% |
| Nantahala Capital Management | 816,830 | $44,419,000 | 1.96% |
| Orbimed Advisors | 1,679,417 | $91,327,000 | 1.48% |
| CHI Advisors LLC | 62,229 | $3,384,000 | 1.44% |
| Parkman Healthcare Partners LLC | 72,690 | $3,953,000 | 1.16% |